RxDoctor Payments DataLook up a doctor →

Crystal Davison, APRN

Family · Lees Summit, MONPI 1467728089

Payments from drug & device makers

$15,684in general payments, 2019–2025

Across 558 payments — averaging $28.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Jazz Pharmaceuticals Inc.$2K
  • Inspire Medical Systems, Inc.$2K
  • Harmony Biosciences LLC$1K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Sanofi$1K
  • plus $6K from 40 others

What the payments were for

  • Consulting fees$1501%
  • Travel & lodging$9336%
  • Food & beverage$14,20191%
  • Education$4003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,684 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$49,563
Medicare patients
324
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Sodium Oxybate11$210,175
WakixPitolisant Hcl12$182,894
Trelegy ElliptaFluticasone/Umeclidin/Vilanter33$33,020
Breo ElliptaFluticasone/Vilanterol39$16,653
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$9,141
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,359
Armodafinil35$4,956
Modafinil38$3,376
Albuterol Sulfate HfaAlbuterol Sulfate74$1,525
Zaleplon33$595
Eszopiclone32$556
Zolpidem Tartrate45$475
Fluticasone Propionate22$430
Ipratropium Bromide16$418
Levocetirizine Dihydrochloride24$314

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$1,490$182,89412 claims
GSKTrelegy Ellipta, Breo Ellipta$820$49,67372 claims
Boehringer IngelheimStiolto Respimat$836$9,14114 claims
AstraZenecaBreztri Aerosphere$2,173$8,35913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Lees Summit

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →